Browse > Article
http://dx.doi.org/10.1080/12298093.2018.1461316

Hyperlipidemic Inhibitory Effects of Phellinus pini in Rats Fed with a High Fat and Cholesterol Diet  

Im, Kyung Hoan (Division of Life Sciences, Incheon National University)
Choi, Jaehyuk (Division of Life Sciences, Incheon National University)
Baek, Seung-A (Division of Life Sciences, Incheon National University)
Lee, Tae Soo (Division of Life Sciences, Incheon National University)
Publication Information
Mycobiology / v.46, no.2, 2018 , pp. 159-167 More about this Journal
Abstract
This study evaluated the in vitro and in vivo hypolipidemic effects of the medicinal mushroom Phellinus pini. The methanol extract (ME) of the fruiting body of Ph. pini was active against pancreatic lipase and cholesterol esterase with 99.14% and 67.23% inhibited activity at 1.0 mg/mL, respectively. It also inhibited 81.81% and 55.33% of ${\alpha}$-glucosidase and ${\alpha}$-amylase activities, respectively, at 2.0 mg/mL. Hyperlipidemia as induced by feeding rats with a high fat and cholesterol diet (HFC). HFC supplemented with a 5% fruiting body powder of Ph. pini (HFC + PhP) significantly reduced plasma total cholesterol, low-density lipoprotein cholesterol, and triglycerides in rats compared with HFC. The reduced levels were comparable to rats fed the normal control diet (NC). The atherogenic index of HFC + PhP rats was significantly lower than that of the HFC rats. The excretion of fecal total lipid and cholesterol in the HFC + PhP rats was significantly higher than those in the NC and HFC rats. Histopathological examinations demonstrated scant deposition of lipids in the liver of rats fed HFC + PhP. The dietary supplementation with the fruiting body powder provided natural plasma lipid and glucose lowering effects in experimental rats without adverse effects on the plasma biochemical parameters and liver function related enzyme activities. Therefore, the hypolipidemic effects of Ph. pini may be due to the inhibitory effects on pancreatic lipase, cholesterol esterase, ${\alpha}$-glucosidase, and ${\alpha}$-amylase, and excretion of excess lipids and cholesterol in the feces.
Keywords
Atherogenic index; cholesterol; hyperlipidemia; lipid profiles; Phellinus pini;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schwandt P. Drug interactions and side effects of hypolipidemic drugs. Int J Clin Pharmacol Biopharm. 1979;17:351-356.
2 Alam N, Yoon KN, Lee JS, et al. Dietary effect of Pleurotus eryngii on biochemical function and histology in hypercholesterolemic rats. Saudi J Biol Sci. 2011;18:403-409.   DOI
3 Wadhera RK, Steen DL, Khan I, et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipid. 2016;10:472-489.   DOI
4 Yoon KN, Alam N, Lee JS, et al. Antihyperlipidemic effect of dietary Lentinus edodes on plasma, feces and hepatic tissues in hypercholesterolemic rats. Mycobiology. 2011;39:96-102.   DOI
5 Wahl PW, Walden CE, Knopp RH, et al. Lipid and lipoprotein triglyceride and cholesterol interrelationships:effects of sex, hormone use, and hyperlipidemia. Metab Clin Exp. 1984;33:502-508.   DOI
6 Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373-418.   DOI
7 Esmaillzadeh A, Azadbakht L. Food intake patterns may explain the high prevalence of cardiovascular risk factors among Iranian women. J Nutr. 2009;138:1469-1475.
8 Sodjinou R, Agueh V, Fayomi B, et al. Obesity and cardio-metabolic risk factors in urban adults of Benin: relationship with socio-economic status, urbanisation, and lifestyle patterns. BMC Public Health. 2008;8:1-13.   DOI
9 Endo A. The discovery and development of HMGCoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
10 Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27:269-273.   DOI
11 Ibrahim R. Diabetes mellitus type II: review of oral treatment options. Int J Pharm Pharmaceut Sci. 2010;2:21-30.
12 Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-1951.   DOI
13 Laoufi H, Benariba N, Adjdir S, et al. In vitro ${\alpha}$-amylase and ${\alpha}$-glucosidase inhibitory activity of Ononis angustissima extracts. J Appl Pharmaceut Sci. 2017;7:191-198.
14 Ying JZ, Mao XL, Ma QM, et al. Icons of medicinal fungi from China. Beijing: Science Press;1987.
15 Pak WH, Lee HD. Illustrated book of Korean medicinal mushrooms. 2nd ed. Seoul: Kyo-Hak Publishing Co. Ltd; 2003.
16 Kim JS, Kwon CS, Son KH. Inhibition of ${\alpha}$-glucosidase and amylase by Luteolin, a flavonoid. Biosci Biotech Biochem. 2000;64:2458-2461.   DOI
17 Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
18 Dastjerdi MZ, Namjoyan F, Azemi ME. Alpha amylase inhibition activity of some plants extract of Teucrium species. J Biol Sci Opin. 2015;7:26-31.
19 Kim YS, Lee YM, Kim HJ, et al. Anti-obesity effect of Morus bombycis root extract: anti-lipase activity and lipolytic effect. J Ethnopharmacol. 2010;130:621-624.   DOI
20 Pietsch M, Gutschow M. Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition. J Med Chem. 2005;48:8270-8288.   DOI
21 Bayliss HO. Lipids. In: Bancroft JD, Stevens A, editors. Theory and practice of histological techniques. Edinburgh: Churchill Livingstone;1990. p. 215-244.
22 Santhoshkumar S, Nagarajan N. In vitro antioxidant and antidiabetic activity of methanol extract of wild mushroom Ganoderma lucidum (Curtis) P. Karst. Int J Biosci Nanosci. 2014;1:77-85.
23 Su CH, Laib MN, Ng LT. Inhibitory effects of medicinal mushrooms on ${\alpha}$-amylase and aglucosidase-enzymes related to hyperglycemia. Food Funct. 2013;4:644-649.   DOI
24 Maqsood M, Ahmed D, Atique I, et al. Lipase inhibitory activity of Lagenaria siceraria fruit as a strategy to treat obesity. Asian Pac J Trop Med. 2017;10:305-310.   DOI
25 Slanc P, Doljak B, Mlinari A, et al. Screening of wood damaging fungi and macrofungi for inhibitors of pancreatic lipase. Phytother Res. 2004;18:758-762.   DOI
26 Lee JK, Jang JH, Lee JT, et al. Extraction and characteristics of anti-obesity lipase inhibitor from Phellinus linteus. Mycobiology. 2010;38:52-57.   DOI
27 Bobek P, Ozdin L, Kuniak L. Regulation of cholesterol metabolism with addition of oyster mushroom (Pleurotus ostreatus) in rats with hypercholesterolemia. Cas Lek Cesk. 1997;136:186-190.
28 Chiou SY, Lai GW, Lin G. Kinetics and mechanisms of cholesterol esterase inhibition by cardiovascular drugs in vitro. Indian J Biochem Biophys. 2006;43:52-55.
29 Alam N, Yoon KN, Lee TS, et al. Hypolipidemic activities of dietary Pleurotus ostreatus in hypercholesterolemic rats. Mycobiology. 2011;39:45-51.   DOI
30 Mori K, Kobayashi C, Tomita T, et al. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake) and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res. 2008;28:335-342.   DOI
31 Golomb BA, Evans MA, Shimada Y, et al. Eritadenine induced alterations of plasma lipoprotein lipid concentrations and phosphatidylcholine molecular species profile in rats fed cholesterolfree and cholesterol-enriched diets. Biosci Biotechnol Biochem. 2003;67:996-1006.   DOI
32 Cheung PCK. The hypercholesterolemic effect of two edible mushrooms: Auricularia auricula (treeear) and Tremella fuciformis (white jelly-leaf) in hypercholesterolemic rats. Nutr Res. 1996;16:1721-1725.   DOI
33 Ramachandra SG, Ramesh V, Krishnamurthy HN, et al. Normal hematological and plasma biochemical parameters of the captive bonnet monkey (Maccaca radiata). Primates. 1998;39:127-134.   DOI
34 Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59:2223-2230.
35 Hyder MA, Hasan M, Mohieldein AH. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. Eur J Experi Biol. 2013;3:280-284.
36 Lunagariya NA, Patel NK, Jagtap SC, et al. Inhibitors of pancreatic lipase: state of the art and clinical perspectives. Excli J. 2014;13:897-921.